Rigshospitalet — Sponsor Intelligence | 97 EU Trials

Filter these 97 trials by condition, phase, country and more.

Open in Search →

97 Registered trials

55 Recruiting

28 Completed trials

12 Countries active

147 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 15 Phase II: 33 Phase I/II: 3 Phase III/IV: 4 Phase IV: 36 Phase I: 1 Phase I (Other): 4 Phase I (FiH): 1

Oversight events:

3 serious breaches 3 temporary halts 1 urgent safety measure 1 unexpected event across 6 trials

View oversight register →

100%

28 of 28 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Neuroendocrine carcinoma metastatic 2 Neuroendocrine carcinoma 2 Pulmonary embolism 2 Breast cancer 1 Coma 1 Glioma 1 HER2 protein overexpression 1 Malignant glioma 1 Pulmonary arterial hypertension 1 Trigeminal neuralgia 1 Acute myeloid leukaemia 1 Antiphospholipid antibodies 1

Top IMPs

SODIUM CHLORIDE 12 SEMAGLUTIDE 5 (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE 3 DEXAMETHASONE DISODIUM PHOSPHATE 3 FLUDEOXYGLUCOSE (18F) 3 APOMORPHINE HYDROCHLORIDE HEMIHYDRATE 2 ATEZOLIZUMAB 2 CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS 2 DEXAMETHASONE PHOSPHATE 2 DICLOFENAC SODIUM 2 DRY EXTRACT FROM PSILOCYBE CUBENSIS (15-25:1), EXTRACTION SOLVENT: METHANOL 2 DUPILUMAB 2

All trials — page 2

97 total

[68Ga]Ga-FAPI PET/CT for response evaluation during immune checkpoint inhibitor therapy in malignant melanoma Recruiting

2023-509549-11-00 Phase II 1 country (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHY…
Tapering of biologics in chronic rhinosinusitis with nasal polyps Recruiting

2024-519758-35-01 Phase IV 1 country
Ikervis in the Treatment of Atopic Keratoconjunctivitis - a Prospective, Randomized, Placebo-Controlled Trial Recruiting

2022-500633-92-00 Phase II 1 country CICLOSPORIN
FESSnonFESS Recruiting

2024-514632-24-02 Phase III/IV 1 country
Additive Benefits of Semaglutide for open-AngLe glaucoma – an Opportunity for Neuroprotection (ABSALON) Recruiting

2024-518510-87-00 Phase IV 1 country SEMAGLUTIDE
Klinefelter syndrome – the effect of Testosterone treatment In PubertY A randomized, double-blind placebo-controlled intervention study ‘Th… Recruiting

2023-505854-16-00 Phase IV 1 country TESTOSTERONE
Boosting recovery through excitation of arousal and awareness in comatose patients: Dose finding study (BREA2KTHROUGH DOSEFINDER) Recruiting

2023-503617-30-02 Phase I (Other) 1 country APOMORPHINE HYDROCHLORIDE HEMIHYDRATE; DRY EXTRACT FROM PSILOCYBE CUBENSIS (15-2…
A randomized phase III trial with lomustine versus lomustine and bevacizumab for patients with recurrent glioblastoma Recruiting

2024-519437-27-02 Phase III 1 country BEVACIZUMAB; LOMUSTINE
Measuring the levels of LSD in the human brain using neuroimaging Recruiting

2024-519564-41-00 Phase I (Other) 1 country
Intraglandular treatment with adipose derived mesenchymal stem cells in patients with xerostomia due to Sjögrens syndrome (ASSIX) Recruiting

2024-516715-25-00 Phase I/II 1 country CL-AD-MSC-002
Gabapentin for nerve pain in the leg from the lower back Recruiting

2023-508537-13-01 Phase III 1 country GABAPENTIN
Safety and efficacy of botulinum toxin A in patients with posttraumatic headache: a double-blind, randomized, placebo-controlled, parallel-g… Recruiting

2024-515901-24-00 Phase III 1 country SODIUM CHLORIDE
REINFORCE – Reducing infection-related readmissions following cystectomy. Recruiting

2024-514312-27-00 Phase IV 1 country AMOXICILLIN; AMOXICILLIN, CLAVULANIC ACID; CEFUROXIME AXETIL; CIPROFLOXACIN; FLU…
Ketamine sedation as neuroprotective agent following out-of-hospital cardiac arrest Recruiting

2024-515987-29-00 Phase III/IV 1 country ESKETAMINE HYDROCHLORIDE; PROPOFOL
New Beacon Recruiting

2024-518419-20-00 Phase II 1 country
VEX-AZA: Treating VEXAS Syndrome with Azacitidine. A Single-Arm, Multicenter Phase II Study on the Efficacy and Safety of Azacitidine in Pat… Recruiting

2024-510715-30-00 Phase II 4 countries
Local Antibiotics for Women Undergoing Breast Reconstruction Surgery with Implants Recruiting

2024-517672-38-00 Phase III 1 country CEFAZOLIN SODIUM; SODIUM CHLORIDE
Semaglutide Treatment for Prevention of Toxicity in High-dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation Recruiting

2022-502139-20-00 Phase II 1 country SEMAGLUTIDE
Safety and efficacy of oral semaglutide in hyperglycaemic patients after renal transplantation Recruiting

2023-504159-29-01 Phase II 1 country SEMAGLUTIDE
The Neurobiological Effect of 5-HT2AR Modulation Recruiting

2024-515961-33-00 Phase I (Other) 1 country
PHASE II STUDY OF AZACITIDINE IN COMBINATION WITH LOW DOSE INTENSITY VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH INTEGRATION OF … Recruiting

2023-510415-19-00 Phase II 4 countries DECITABINE, CEDAZURIDINE
DAPHNE Recruiting

2024-510746-14-00 Phase IV 1 country IXEKIZUMAB
Pericapsular nerve group (PENG) block for postoperative pain after peri-acetabular osteotomy Recruiting

2024-513688-25-01 Phase IV 1 country ROPIVACAINE HYDROCHLORIDE
Adjuvant therapy in high risk adrenocortical carcinoma (ADIUVO-2) Recruiting

2022-500013-32-01 Phase III 3 countries

Showing 25–48 of 97 trials

← All sponsors A–Z